Compare Cancer Treatment Destinations
CancerCareE is not a hospital, not a medical provider. We are an independent platform providing data-driven comparisons to help you understand treatment options across 7 countries.
- ✦ $0 patient fees — We never charge patients
- ✦ Evidence-based comparisons of costs, trials & quality
- ✦ At your request, we introduce you to vetted institutions
- ✦ All medical decisions made by licensed physicians
Comparing Treatment Destinations
There is no universal "best" country — only the country that best matches your diagnosis, priorities, and circumstances. CancerCareE provides independent information; we do not make recommendations.
What matters most to you?
For patients prioritizing access to clinical trials at lower cost, China hosts the world's largest ecosystem of CAR-T trials, with prices from $30,000–$80,000.
For patients focused on regulator-approved treatments and hospital quality, South Korea offers FDA-approved CAR-T products and JCI-accredited hospitals, with costs $250,000–$350,000.
For patients who want the longest safety record, the USA has the longest track record, with costs $373,000–$475,000.
Find Your Match
Answer 4 quick questions for informational guidance. Not a recommendation.
2. Is cost a primary factor?
3. Interested in clinical trials?
4. English support essential?
Informational only. Discuss with your physician.
Which Destinations Match Your Priorities?
Three common patient profiles and countries often explored based on available data.
Cost-Conscious
- Often explored: Patients seeking lower costs
- Frequently considered: China ($30K–$80K)
- Also explored: India ($40K–$90K)
- Key difference: Significant cost variation vs USA
- Commonly for: Blood cancers, solid tumor trials
Quality-Focused
- Often explored: Patients wanting global hospital ratings
- Frequently considered: South Korea ($250K–$350K)
- Also explored: Singapore ($200K–$300K)
- Key feature: JCI-accredited hospitals
- Commonly for: FDA-approved CAR-T, premium care
Innovation-Exploring
- Often explored: Patients wanting trial information
- Frequently considered: China (700+ active trials)
- Also explored: USA (200+ active trials)
- Key feature: Access to next-generation therapies
- Commonly for: Solid tumors, rare cancers
Treatment Availability by Cancer Type
Current clinical trial and treatment availability by cancer type.
| Cancer Type | Countries with Active Programs | Context |
|---|---|---|
| Leukemia | China, USA, South Korea | High volume of CD19-targeted CAR-T trials |
| Lymphoma | China, USA | Extensive trial networks for CD19 and dual-target |
| Multiple Myeloma | USA, China | BCMA-targeted CAR-T trials in both countries |
| Liver Cancer | China | GPC3-targeted CAR-T trials |
| Pancreatic Cancer | China, Germany | Claudin18.2-targeted trials |
| Lung Cancer | China, Germany, USA | Diverse trial landscape |
| Glioblastoma | China, Germany | Studies on IL13Rα2 and novel targets |
| Breast Cancer | South Korea, Germany, USA | Strong surgical and systemic therapy |
Country Comparison
Side-by-side comparison across key factors (2025–2026 data).
| Country | CAR-T Cost | Total Cost | Hospitals | Trials | Approval | Wait | Notable For |
|---|---|---|---|---|---|---|---|
🇨🇳ChinaCost-Effective |
$30K–$80K | $45K–$120K | 80+ | 700+ | NMPA | 2–4w | Trials, Cost |
🇮🇳India |
$40K–$90K | $55K–$130K | 40+ | ~50 | NABH | 4–8w | Cost, English |
🇹🇷Turkey |
$80K–$150K | $100K–$190K | 30+ | ~30 | JCI | 3–6w | Location |
🇸🇬Singapore |
$200K–$300K | $240K–$370K | 15+ | ~15 | JCI | 4–6w | Premium |
🇰🇷South Korea |
$250K–$350K | $290K–$420K | 25+ | ~25 | JCI | 4–8w | FDA Products |
🇩🇪Germany |
$180K–$350K | $220K–$420K | 20+ | ~80 | JCI | 6–10w | Research |
🇺🇸USA |
$373K–$475K | $400K–$550K | 25+ | ~200 | FDA | 8–12w | Track Record |
Explore Each Destination
Detailed guides for each country.
China
- World's largest CAR-T trial ecosystem
- Significant cost difference vs USA
- Novel targets: Claudin18.2, GPC3
South Korea
- JCI-accredited hospitals
- Yescarta (FDA-approved) available
- Excellent English support
Turkey
- JCI-accredited hospitals
- 3–6 hour flights from Middle East
- Arabic-speaking coordinators
India
- Lowest costs outside China
- English widely spoken
- Growing CAR-T programs
Singapore
- National Cancer Centre
- World-class infrastructure
- Safe, clean environment
Germany
- Charité, Heidelberg, LMU
- EMA-approved products
- Strong research programs
USA
- 5 FDA-approved CAR-T products
- MD Anderson, MSK
- Insurance coverage available
Country Scores
Data-driven comparison across four weighted factors.
Key Factors to Consider
Six critical factors to discuss with your treating physician.
Cost & Insurance
Total care costs vary significantly between countries.
- Drug cost: $30,000 in China up to $475,000 in the USA
- Hospital stay and doctor fees
- Travel, housing, and food
- Follow-up care costs
Hospital Quality
Look for global quality indicators.
- JCI approval — global standard
- Published patient outcomes
- Experience with your cancer type
- Fully equipped ICU and emergency team
Treatment Availability
Different countries offer different access.
- FDA- or EMA-approved products
- Clinical trials for next-generation therapies
- Check if your exact cancer type is covered
- Combination therapy options
Language & Communication
Clear communication is essential.
- Doctors who speak your language
- Professional medical translators
- Medical records fully translated
- Coordinator available 24/7
Travel & Logistics
The journey itself matters significantly.
- Flight duration from your home
- Visa requirements and approval times
- Accommodation near the hospital
- Family visit feasibility
Continuity of Care
Treatment doesn't end when you fly home.
- Full discharge summary in English
- Direct communication between doctors
- Clear long-term follow-up plan
- Coordination with your local physician
Data Sources & Methodology
Our comparison is data-driven and transparent.
Data Sources (Last Updated: July 2026)
- Clinical Trial Registries: ClinicalTrials.gov, ChiCTR, EU Clinical Trials Register
- Regulatory Bodies: FDA, EMA, NMPA, MFDS, CDSCO
- Hospital Quality: JCI official accredited organization listings
- Cost Data: Aggregated from hospital international patient departments, 2025–2026 literature
- Clinical Guidelines: NCCN, ESMO, ASCO
Scoring Methodology
Each country receives a weighted score (0–100) based on four factors:
| Factor | Weight | What We Measure |
|---|---|---|
| Clinical Evidence & Trials | 30% | Active trials, published outcomes, approvals |
| Cost Accessibility | 25% | Total cost of care vs global average, transparency |
| Regulatory & Hospital Quality | 25% | JCI accreditation, regulatory framework, safety |
| International Patient Support | 20% | Language, visa facilitation, international departments |
Limitations
This comparison provides general information based on aggregate data. It is not a substitute for personalized medical advice. Always consult with qualified healthcare providers.
Frequently Asked Questions
Ready to Explore Your Options?
Submit an introduction request and we'll forward your contact information to partner centers. No medical data is collected.
Independent • No patient fees • No medical data collected